Statement of Changes in Beneficial Ownership (4)

Date : 09/12/2019 @ 12:20AM
Source : Edgar (US Regulatory)
Stock : Acadia Pharmaceuticals Inc (ACAD)
Quote : 41.68  0.0 (0.00%) @ 10:10AM

Statement of Changes in Beneficial Ownership (4)

FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Miller Eric Alejandro
2. Issuer Name and Ticker or Trading Symbol

ACADIA PHARMACEUTICALS INC [ ACAD ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Controller & PAO
(Last)          (First)          (Middle)

C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, SUITE 300
3. Date of Earliest Transaction (MM/DD/YYYY)

9/9/2019
(Street)

SAN DIEGO, CA 92130
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/9/2019    M    7500  A $20.65  12145 (1) D   
Common Stock  9/9/2019    M    3900  A $32.28  16045  D   
Common Stock  9/9/2019    M    6063  A $29.24  22108  D   
Common Stock  9/9/2019    M    4439  A $36.54  26547  D   
Common Stock  9/9/2019    M    4593  A $35.80  31140  D   
Common Stock  9/9/2019    M    1972  A $16.50  33112  D   
Common Stock  9/9/2019    S    28467  D $39.49 (2) 4645  D   
Common Stock  9/11/2019    S    4645  D $41.18 (3) 0  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $20.65  9/9/2019    M        7500    (4) 5/29/2024  Common Stock  7500  $0.00  0  D   
Stock Option (Right to Buy)  $32.28  9/9/2019    M        3900    (4) 1/25/2025  Common Stock  3900  $0.00  0  D   
Stock Option (Right to Buy)  $29.24  9/9/2019    M        6063    (5) 1/5/2026  Common Stock  6063  $0.00  552  D   
Stock Option (Right to Buy)  $36.54  9/9/2019    M        4439    (6) 3/7/2027  Common Stock  4439  $0.00  2911  D   
Stock Option (Right to Buy)  $35.80  9/9/2019    M        4593    (7) 9/6/2027  Common Stock  4593  $0.00  4594  D   
Stock Option (Right to Buy)  $16.50  9/9/2019    M        1972    (8) 4/6/2028  Common Stock  1972  $0.00  3598  D   

Explanation of Responses:
(1)  Includes 860 shares of the Issuer's common stock acquired by the reporting person on November 15, 2018 and 573 shares of the Issuer's common stock acquired by the reporting person on May 15, 2019 pursuant to an employee stock purchase program.
(2)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.49 to $39.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
(3)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.1401 to $41.255, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
(4)  The option is fully vested and exercisable.
(5)  25% of the shares subject to the Stock Option vested and became exercisable on January 1, 2017, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
(6)  25% of the shares subject to the Stock Option vested and became exercisable on March 8, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
(7)  25% of the shares subject to the Stock Option vested and became exercisable on September 7, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
(8)  25% of the shares subject to the Stock Option vest and become exercisable on April 7, 2019, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Miller Eric Alejandro
C/O ACADIA PHARMACEUTICALS INC.
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO, CA 92130


Controller & PAO

Signatures
/s/ Austin D. Kim, Attorney-in-Fact 9/11/2019
**Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart

1 Year : From Sep 2018 to Sep 2019

Click Here for more Acadia Pharmaceuticals Charts.

Acadia Pharmaceuticals (NASDAQ:ACAD)
Intraday Stock Chart

Today : Friday 20 September 2019

Click Here for more Acadia Pharmaceuticals Charts.

Latest ACAD Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.